{ "vercy": "1.0-draft", "publication": { "status": "research-draft", "adjudicationStatus": "unreviewed", "publishableCanonical": false, "generatedAt": "2026-09-12T10:53:22Z", "providers": [ "Codex" ], "breadth": "recalled by Codex without web access - no source was read", "missingProviders": [], "pass": 2, "cost": { "grok": { "seconds": 22.6, "error": "Reading additional input from stdin...\nOpenAI Codex v0.153.4\n--------\nworkdir: R:\\02_PROJECTS\\02_Meta_Models_Platforms\\Ver.cy\\current\\thing-registry-backlog\nmodel: gpt-6-astra\nprovider: openai\napproval: never\nsandbox: read-only\nreasoning effort: none\nreasoning summaries: none\nsession id: 01a0953f-0782-7462-823b-fc5389a6b3c8\n--------\nuser\nDescribe what is already known about one registered thing. Answer as JSON only, no prose around it.\n\nThing: laronidase\nSense to describe: (none recorded)\nDomain code: PHY.MAT\nAlso known as: (none)\n\n\nContext for this batch of 1001 things:\n# Batch 044: 1001 regi", "usd": 0.0, "recall": true }, "codex": { "seconds": 71.7, "error": "Reading additional input from stdin...\nOpenAI Codex v0.153.4\n--------\nworkdir: R:\\02_PROJECTS\\02_Meta_Models_Platforms\\Ver.cy\\current\\thing-registry-backlog\nmodel: gpt-6-astra\nprovider: openai\napproval: never\nsandbox: read-only\nreasoning effort: none\nreasoning summaries: none\nsession id: 01a0953f-0772-7971-b9ba-5ba0b92c2c1d\n--------\nuser\nYou are drafting a Vercy meta-model for one registered thing. Answer as JSON only, no prose around it.\n\nThing: laronidase\nRegistry id: vr.tr.laronidase\nPlane / domain: PHY / PHY.MAT\nRegistry definition: (none recorded)\nNames folded into this entry: (none)\n\n\nCo" } }, "enrichment": { "pass": 3, "engine": "claude", "producedAt": "2026-10-06T12:00:00Z", "ingestedAt": "2026-10-06T08:41:21+00:00", "fields": [ "agent_conduct", "ethics", "failure_modes_and_hazards", "owners", "visual_identification" ] }, "gate": { "passed": true, "version": "1.0", "at": "2026-10-07T10:10:28+00:00", "evidence": [ "completeness 1.00", "sense: Wikidata description", "2 live sources", "review by codex: pass" ] } }, "metaModel": { "id": "THING-Q20801774", "registryId": "vr.tr.laronidase", "name": "laronidase", "version": "0.1.0-research.1", "entryKind": "thing", "family": "Thing Registry", "domain": [ "PHY.MAT" ], "status": "research-draft" }, "canonicalUrl": "https://ver.cy/models/thing/q20801774/", "model": { "registry_id": "vr.tr.laronidase", "name": "laronidase", "purpose": "Enable an agent to recognise laronidase, assess the identity and functional quality of a material lot, and determine which handling or use decisions require product-specific evidence.", "definition": "Laronidase is a recombinant form of human α-L-iduronidase used as enzyme replacement therapy for mucopolysaccharidosis type I, restoring lysosomal breakdown of the glycosaminoglycans dermatan sulfate and heparan sulfate.", "scope_statement": "This model owns vr.tr.laronidase in PHY / PHY.MAT: the recombinant human alpha-L-iduronidase active substance, its molecular identity, enzymatic function, material quality, provenance and relationships to authorised medicinal products.", "in_scope": [ "Recombinant protein identity and distinction from endogenous alpha-L-iduronidase", "Protein sequence, glycosylation and molecular heterogeneity", "Catalytic potency and evidence of cellular enzyme delivery", "Lot-specific purity, degradation and handling state", "Active-substance provenance and links to product-specific regulatory evidence" ], "out_of_scope": [ "Aldurazyme packaging, excipient formulation and finished-product presentation", "Mucopolysaccharidosis I diagnosis and disease progression", "Patient-specific prescribing, dosing and infusion management", "Detailed cell-culture and purification process execution", "IDUA gene variants, gene therapies and endogenous enzyme physiology" ], "distinguishing_features": [ "Must be identified as recombinant human alpha-L-iduronidase; a record of endogenous enzyme activity alone does not establish laronidase identity. [EMA product information](https://www.ema.europa.eu/en/documents/product-information/aldurazyme-epar-product-information_en.pdf)", "Its catalytic identity concerns removal of terminal alpha-L-iduronic acid residues from dermatan sulfate and heparan sulfate. [DailyMed prescribing information](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a80ac249-cae4-41f3-88bb-344088b20e60)", "The reference medicinal substance is produced in CHO cells and has a mature 628-residue protein with six N-linked oligosaccharide modification sites; sequence and glycan evidence must accompany identity comparisons. [DailyMed prescribing information](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a80ac249-cae4-41f3-88bb-344088b20e60)", "Aldurazyme is a medicinal product containing laronidase; its vial concentration, excipients and storage instructions are contextual product attributes rather than universal substance constants." ], "characteristics": [ { "name": "Molecular identity evidence", "kind": "relation", "unit_or_values": "Reference sequence, peptide map, identity assay and versioned reference material", "why_it_matters": "Distinguishes the registered substance from another recombinant enzyme or an incompletely characterised research reagent." }, { "name": "Production origin", "kind": "category", "unit_or_values": "Expression host, manufacturer and process version; CHO origin for the referenced medicinal substance", "why_it_matters": "Production context supports traceability and interpretation of glycosylation and impurity profiles." }, { "name": "Glycosylation profile", "kind": "measurement", "unit_or_values": "Site occupancy and relative glycoform abundance in %, with analytical method", "why_it_matters": "Protein sequence alone cannot describe the material's glycan-dependent properties." }, { "name": "Catalytic activity", "kind": "measurement", "unit_or_values": "U/mL or U/mg with substrate, pH, temperature and assay definition", "why_it_matters": "Mass concentration does not establish functional enzyme content; activity results require compatible assay conditions." }, { "name": "Protein concentration", "kind": "measurement", "unit_or_values": "mg/mL with method and sample preparation", "why_it_matters": "Supports material accounting and calculation of specific activity without equating protein mass with potency." }, { "name": "Cellular uptake and localisation evidence", "kind": "relation", "unit_or_values": "Cell system, uptake assay, localisation assay and reference comparator", "why_it_matters": "Catalytic activity in solution does not by itself establish effective intracellular delivery." }, { "name": "Purity and degradation profile", "kind": "measurement", "unit_or_values": "Relative abundance of aggregates, fragments and other species; assay-specific impurity concentrations", "why_it_matters": "A positive identity result can coexist with degradation or unacceptable contamination." }, { "name": "Material disposition", "kind": "state", "unit_or_values": "Unassessed, quarantined, released for a specified use, rejected or expired", "why_it_matters": "Prevents an agent from treating identified material as automatically suitable for clinical or research use." }, { "name": "Handling history", "kind": "relation", "unit_or_values": "Time-temperature record, freeze-thaw events, agitation, dilution and container contacts", "why_it_matters": "Lot condition must be interpreted against stability evidence applicable to its formulation and container." }, { "name": "Regulatory context", "kind": "relation", "unit_or_values": "Jurisdiction, authorised product, source document, revision date and intended use", "why_it_matters": "Approval of a containing product does not authorise every material carrying the substance name." } ], "affordances": [ "Compare a candidate lot with documented laronidase identity criteria.", "Evaluate potency results while preserving assay definitions and uncertainty.", "Compare lot quality against specifications applicable to the intended use.", "Flag handling excursions for evidence-based disposition.", "Link the active substance to an authorised product and its current instructions.", "Identify missing evidence that prevents release, substitution or a functional-equivalence claim." ], "agent_conduct": { "may": [ "Explain what laronidase is used for, citing approved product information.", "Report documented safety warnings, such as infusion reactions, from official labels." ], "must_not": [ "Prescribe, change or stop laronidase treatment for a person.", "Give dosing advice for a specific patient.", "Present unapproved uses as established treatment.", "Share a patient's diagnosis or treatment records without consent." ], "requires_human": [ "Any treatment decision, made by the patient's clinicians.", "Access programmes or funding decisions for an individual." ] }, "ethics": { "considerations": [ "MPS I is a rare disease; access to costly enzyme therapy raises questions of fairness.", "Patients include young children who depend on caregivers for decisions." ], "affected_parties": [ "Patients with MPS I", "Families and caregivers", "Clinicians" ] }, "owners": { "steward": "The marketing authorization holder for the product; the treating clinician for each patient.", "master_systems": [ "Medicines regulator product registers", "Rare disease patient registries" ] }, "visual_identification": [ "Supplied as a clear, colourless to pale yellow solution in glass vials for intravenous infusion.", "Identity is settled by the product label and batch, not by appearance." ], "failure_modes_and_hazards": [ "Infusion-related reactions, including severe allergic reactions, can occur.", "Interrupted supply or cold-chain failure can deprive patients of therapy." ], "what_it_is_for": [ "Laronidase is used in specialist clinical care as enzyme replacement therapy for people with mucopolysaccharidosis type I.", "Its identity, enzyme activity, formulation and storage history are assessed in pharmaceutical manufacture and clinical supply using product-specific evidence." ], "standards_and_regulation": [ "The World Health Organization Collaborating Centre for Drug Statistics Methodology classifies laronidase under ATC code A16AB05." ] }, "sources": [ { "id": "wikidata", "title": "Wikidata item Q20801774: laronidase", "url": "https://www.wikidata.org/wiki/Q20801774", "url_status": "live", "what_it_supports": "identity and sense of the item", "checked_by": "wikidata-api" }, { "id": "wikipedia-en", "title": "Wikipedia: Iduronidase", "url": "https://en.wikipedia.org/wiki/Iduronidase", "url_status": "live", "what_it_supports": "general description of the item", "checked_by": "wikidata-api sitelink" } ], "structure": { "bundles": [ { "id": "recombinant-enzyme-identity", "name": "Recombinant enzyme identity", "description": "Establishes what qualifies as laronidase and how identity is evidenced.", "rationale": "A shared enzyme name or therapeutic purpose is insufficient to establish active-substance identity.", "layers": [ { "id": "substance-boundary", "name": "Substance boundary", "description": "Separates the recombinant active substance from related biological and product entities.", "findings": [ { "id": "laronidase-entity-boundary", "name": "Laronidase entity boundary", "description": "Record whether evidence describes laronidase material, endogenous alpha-L-iduronidase, an experimental construct or a containing medicinal product.", "questions": [ { "text": "What evidence identifies this entity as laronidase rather than merely an alpha-L-iduronidase preparation?", "kind": "definition", "id": "laronidase-entity-boundary-q01" }, { "text": "Which recorded properties belong to the active substance and which belong to Aldurazyme or another formulation?", "kind": "boundary", "id": "laronidase-entity-boundary-q02" } ] } ] }, { "id": "molecular-reference", "name": "Molecular reference", "description": "Connects identity assertions to protein characterisation and production origin.", "findings": [ { "id": "sequence-and-origin", "name": "Sequence and origin", "description": "Preserve reference sequence, mature-chain processing, expression-host provenance and analytical confirmation without assuming that a matching name establishes equivalence.", "questions": [ { "text": "Which sequence reference and peptide-mapping results support the mature protein identity?", "kind": "provenance", "id": "sequence-and-origin-q01" }, { "text": "Which production host and process version produced the material being assessed?", "kind": "provenance", "id": "sequence-and-origin-q02" } ] } ] } ] }, { "id": "catalysis-and-cellular-delivery", "name": "Catalysis and cellular delivery", "description": "Represents enzyme function and the evidence needed to interpret biological delivery.", "rationale": "An enzyme replacement substance needs separate assessments of catalytic competence and access to its intracellular site of action.", "layers": [ { "id": "enzymatic-potency", "name": "Enzymatic potency", "description": "Makes catalytic measurements interpretable and comparable.", "findings": [ { "id": "activity-unit-definition", "name": "Activity unit definition", "description": "Store assay conditions with each activity result. The EMA product information defines one unit through hydrolysis of one micromole of 4-MUI substrate per minute. [EMA product information](https://www.ema.europa.eu/en/documents/product-information/aldurazyme-epar-product-information_en.pdf)", "questions": [ { "text": "Which substrate, pH, temperature and calibration standard define the reported laronidase activity?", "kind": "measurement", "id": "activity-unit-definition-q01" }, { "text": "Is there validated evidence permitting comparison or conversion between these two activity assays?", "kind": "measurement", "id": "activity-unit-definition-q02" } ] } ] }, { "id": "cellular-function", "name": "Cellular function", "description": "Separates catalytic assay performance from uptake and intracellular function.", "findings": [ { "id": "uptake-and-substrate-processing", "name": "Uptake and substrate processing", "description": "Record cellular uptake, lysosomal localisation and substrate-processing evidence as distinct endpoints, each tied to its experimental system.", "questions": [ { "text": "What experiments demonstrate uptake and lysosomal localisation of this material?", "kind": "provenance", "id": "uptake-and-substrate-processing-q01" }, { "text": "Which cellular substrate-processing endpoint was measured, and how did it compare with a qualified reference?", "kind": "measurement", "id": "uptake-and-substrate-processing-q02" } ] } ] } ] }, { "id": "glycoprotein-quality", "name": "Glycoprotein quality", "description": "Captures molecular heterogeneity and unwanted material in a laronidase lot.", "rationale": "A recombinant glycoprotein cannot be adequately characterised through a single molecular formula or purity percentage.", "layers": [ { "id": "glycan-characterisation", "name": "Glycan characterisation", "description": "Describes glycan structure and its relationship to functional assessment.", "findings": [ { "id": "glycan-profile-comparability", "name": "Glycan profile comparability", "description": "Record site occupancy, glycoform distributions and any measured mannose-6-phosphate attributes, preserving the evidence connecting those measurements to function.", "questions": [ { "text": "Which glycan attributes were measured, with what methods and uncertainty?", "kind": "measurement", "id": "glycan-profile-comparability-q01" }, { "text": "What evidence supports treating the observed glycan differences as acceptable for the proposed use?", "kind": "action", "id": "glycan-profile-comparability-q02" } ] } ] }, { "id": "impurities-and-damage", "name": "Impurities and damage", "description": "Distinguishes protein deterioration from process-related contamination.", "findings": [ { "id": "lot-quality-profile", "name": "Lot quality profile", "description": "Track aggregates, fragments, relevant chemical modifications and process-related impurities against documented specifications.", "questions": [ { "text": "What aggregate, fragment and modification levels were detected relative to the qualified reference?", "kind": "measurement", "id": "lot-quality-profile-q01" }, { "text": "Which residual host-cell protein, DNA and microbiological acceptance criteria apply to this material stage?", "kind": "boundary", "id": "lot-quality-profile-q02" } ] } ] } ] }, { "id": "material-state-and-stability", "name": "Material state and stability", "description": "Connects the physical presentation and handling history to remaining quality.", "rationale": "Storage and compatibility claims for laronidase require a defined formulation, container and material stage.", "layers": [ { "id": "presentation-context", "name": "Presentation context", "description": "Identifies the actual preparation being assessed.", "findings": [ { "id": "preparation-specific-properties", "name": "Preparation-specific properties", "description": "Associate concentration, buffer, pH and container with the preparation; avoid recording solution properties as intrinsic constants of laronidase.", "questions": [ { "text": "Is this bulk active substance, formulated concentrate, diluted preparation or analytical sample?", "kind": "boundary", "id": "preparation-specific-properties-q01" }, { "text": "What concentration, pH, buffer and container describe the assessed sample?", "kind": "measurement", "id": "preparation-specific-properties-q02" } ] } ] }, { "id": "excursion-assessment", "name": "Excursion assessment", "description": "Evaluates departures from supported handling conditions.", "findings": [ { "id": "stability-supported-disposition", "name": "Stability-supported disposition", "description": "Use preparation-specific stability evidence and measured quality to assess temperature excursions, freezing, agitation and surface contact.", "questions": [ { "text": "Which handling events occurred, and which stability study covers their duration and severity?", "kind": "provenance", "id": "stability-supported-disposition-q01" }, { "text": "Does the available evidence support continued use, additional testing or quarantine?", "kind": "action", "id": "stability-supported-disposition-q02" } ] } ] } ] }, { "id": "use-context-and-traceability", "name": "Use context and traceability", "description": "Links substance evidence to qualified lots, product permissions and limits of therapeutic interpretation.", "rationale": "Recognising laronidase does not establish that a particular lot is releasable or that a clinical claim applies.", "layers": [ { "id": "lot-provenance", "name": "Lot provenance", "description": "Connects material identity to documented manufacture and release.", "findings": [ { "id": "qualified-lot-evidence", "name": "Qualified lot evidence", "description": "Preserve manufacturer, batch, certificate of analysis, applicable specification and disposition authority.", "questions": [ { "text": "Which records connect this sample to its manufacturing batch and quality results?", "kind": "provenance", "id": "qualified-lot-evidence-q01" }, { "text": "Who released this lot, against which specification and for which intended use?", "kind": "action", "id": "qualified-lot-evidence-q02" } ] } ] }, { "id": "therapeutic-evidence-boundary", "name": "Therapeutic evidence boundary", "description": "Records applicable medicinal-product evidence without turning it into substance-wide permission.", "findings": [ { "id": "indication-and-safety-context", "name": "Indication and safety context", "description": "Link jurisdiction-specific indications and safety requirements to the containing product. The EMA indication concerns non-neurological manifestations of MPS I; that scope must remain explicit. [EMA product information](https://www.ema.europa.eu/en/documents/product-information/aldurazyme-epar-product-information_en.pdf)", "questions": [ { "text": "Which current product authorisation supports the proposed use in the relevant jurisdiction?", "kind": "provenance", "id": "indication-and-safety-context-q01" }, { "text": "Which claims about tissue delivery, neurological benefit or clinical equivalence remain unsupported for this material?", "kind": "boundary", "id": "indication-and-safety-context-q02" }, { "text": "Which product-specific immunogenicity and infusion-reaction requirements must be passed to the clinical-use model?", "kind": "action", "id": "indication-and-safety-context-q03" } ] } ] } ] }, { "id": "evidence-and-external-alignment", "name": "Evidence and external alignment", "description": "What the world already says about this thing, gathered so the model can be checked against it.", "rationale": "A model that cannot be lined up against existing standards, identifiers and practice cannot be adopted by anyone who already uses them.", "layers": [ { "id": "reported-evidence", "name": "Reported evidence", "description": "Findings from the breadth pass, kept separate from the structural claims.", "findings": [ { "id": "evidence-confidence-notes", "name": "Check these first", "description": "Recalled without web access and unsourced; every item is a lead to verify.", "evidence": [ "This description is recalled knowledge; no sources were consulted.", "Verify current jurisdiction-specific indications and safety wording against official product information.", "Concentration values refer to the formulated concentrate; enzyme activity units depend on the specified assay, and molecular mass varies with glycosylation." ], "questions": [ { "id": "evidence-confidence-notes-q01", "text": "Which of these check these first hold for the sense of laronidase this model covers, and on what evidence?", "kind": "provenance" } ] }, { "id": "evidence-identifiers", "name": "Identifiers and schemes", "description": "Recalled without web access and unsourced; every item is a lead to verify.", "evidence": [ { "scheme": "International Nonproprietary Name (WHO INN)", "value_or_pattern": "laronidase", "note": "Names the active biological substance." }, { "scheme": "WHO Anatomical Therapeutic Chemical classification", "value_or_pattern": "A16AB05", "note": "Classified among enzyme therapies." }, { "scheme": "Enzyme Commission number", "value_or_pattern": "EC 3.2.1.76", "note": "Identifies α-L-iduronidase activity, not a particular manufactured product." } ], "questions": [ { "id": "evidence-identifiers-q01", "text": "Which of these identifiers and schemes hold for the sense of laronidase this model covers, and on what evidence?", "kind": "provenance" } ] }, { "id": "evidence-standards-and-regulation", "name": "Standards and regulation", "description": "Recalled without web access and unsourced; every item is a lead to verify.", "evidence": [ "US FDA prescribing information for Aldurazyme specifies approved uses, administration requirements, and safety warnings.", "European Commission marketing authorisation and EMA product information govern Aldurazyme in the European Union." ], "questions": [ { "id": "evidence-standards-and-regulation-q01", "text": "Which of these standards and regulation hold for the sense of laronidase this model covers, and on what evidence?", "kind": "provenance" } ] }, { "id": "evidence-real-world-use", "name": "Real-world use", "description": "Recalled without web access and unsourced; every item is a lead to verify.", "evidence": [ "Intravenous enzyme replacement therapy for patients with mucopolysaccharidosis type I.", "Treatment of systemic manifestations of deficiency of α-L-iduronidase." ], "questions": [ { "id": "evidence-real-world-use-q01", "text": "Which of these real-world use hold for the sense of laronidase this model covers, and on what evidence?", "kind": "provenance" } ] }, { "id": "evidence-measurements", "name": "Typical measurements", "description": "Recalled without web access and unsourced; every item is a lead to verify.", "evidence": [ { "quantity": "Approximate molecular mass of the glycosylated enzyme", "typical_range": "Approximately 83", "unit": "kDa" }, { "quantity": "Laronidase concentration in Aldurazyme concentrate", "typical_range": "0.58", "unit": "mg/mL" }, { "quantity": "Enzyme activity concentration in Aldurazyme concentrate", "typical_range": "100", "unit": "U/mL" } ], "questions": [ { "id": "evidence-measurements-q01", "text": "Which of these typical measurements hold for the sense of laronidase this model covers, and on what evidence?", "kind": "provenance" } ] }, { "id": "evidence-failure-modes-and-hazards", "name": "Failure modes and hazards", "description": "Recalled without web access and unsourced; every item is a lead to verify.", "evidence": [ "Severe hypersensitivity reactions, including anaphylaxis, can occur.", "Infusion-associated reactions can include fever, chills, rash, and respiratory symptoms.", "Patients with compromised respiratory or cardiac function may experience serious complications during infusion.", "Anti-drug antibodies can develop and may affect enzyme activity or cellular uptake.", "Limited penetration of the blood-brain barrier restricts treatment of central nervous system manifestations." ], "questions": [ { "id": "evidence-failure-modes-and-hazards-q01", "text": "Which of these failure modes and hazards hold for the sense of laronidase this model covers, and on what evidence?", "kind": "provenance" } ] }, { "id": "evidence-regional-variation", "name": "Regional variation", "description": "Recalled without web access and unsourced; every item is a lead to verify.", "evidence": [ "Approved indication wording and prescribing requirements differ between US and European product information." ], "questions": [ { "id": "evidence-regional-variation-q01", "text": "Which of these regional variation hold for the sense of laronidase this model covers, and on what evidence?", "kind": "provenance" } ] }, { "id": "evidence-neighbours", "name": "Neighbouring kinds and how to tell them apart", "description": "Recalled without web access and unsourced; every item is a lead to verify.", "evidence": [ { "name": "α-L-iduronidase", "difference": "The endogenous enzyme is the biological counterpart; laronidase is a manufactured recombinant therapeutic form." }, { "name": "Aldurazyme", "difference": "Aldurazyme is a formulated medicinal product containing laronidase, whereas laronidase names its active substance." }, { "name": "Idursulfase", "difference": "Idursulfase replaces iduronate-2-sulfatase in mucopolysaccharidosis type II, a different enzyme deficiency." }, { "name": "Mucopolysaccharidosis type I", "difference": "This is the inherited disease treated with laronidase, rather than the therapeutic substance." } ], "questions": [ { "id": "evidence-neighbours-q01", "text": "Which of these neighbouring kinds and how to tell them apart hold for the sense of laronidase this model covers, and on what evidence?", "kind": "provenance" } ] } ] } ] } ] }, "openQuestions": [ "Which authoritative sequence reference and identifier records should anchor this registry entry, and do available CAS or database identifiers distinguish laronidase from generic alpha-L-iduronidase?", "Which lot-release limits and validated methods for glycosylation, potency, aggregates and process impurities are publicly available?", "What quantitative evidence connects mannose-6-phosphate attributes with cellular uptake and functional comparability for laronidase?", "Which stability and container-compatibility data apply to bulk active substance, separately from approved concentrate and diluted product?", "Does the existing Vercy catalogue already contain a model that should be the single source of truth for this substance?" ], "statistics": { "bundles": 6, "layers": 11, "findings": 18, "questions": 29 } }